ASSESSMENT OF TREATMENT RESPONSE TO 131I THERAPY FOR PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA IN THE PAST THREE YEARS (Single Institutional Experience)
Badawy, A., Tawakol, A., Abdelmoteleb, A., Ahmad, Y., Kandil, A. (2022). ASSESSMENT OF TREATMENT RESPONSE TO 131I THERAPY FOR PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA IN THE PAST THREE YEARS (Single Institutional Experience). EKB Journal Management System, 25(2), 45-62. doi: 10.21608/egyjnm.2022.168501.1068
Ahmed Mohamed Badawy; Ahmed Tawakol; Asmaa Magdy Abdelmoteleb; Yasser Mohamed Ahmad; Ahmed Kandil. "ASSESSMENT OF TREATMENT RESPONSE TO 131I THERAPY FOR PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA IN THE PAST THREE YEARS (Single Institutional Experience)". EKB Journal Management System, 25, 2, 2022, 45-62. doi: 10.21608/egyjnm.2022.168501.1068
Badawy, A., Tawakol, A., Abdelmoteleb, A., Ahmad, Y., Kandil, A. (2022). 'ASSESSMENT OF TREATMENT RESPONSE TO 131I THERAPY FOR PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA IN THE PAST THREE YEARS (Single Institutional Experience)', EKB Journal Management System, 25(2), pp. 45-62. doi: 10.21608/egyjnm.2022.168501.1068
Badawy, A., Tawakol, A., Abdelmoteleb, A., Ahmad, Y., Kandil, A. ASSESSMENT OF TREATMENT RESPONSE TO 131I THERAPY FOR PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA IN THE PAST THREE YEARS (Single Institutional Experience). EKB Journal Management System, 2022; 25(2): 45-62. doi: 10.21608/egyjnm.2022.168501.1068

ASSESSMENT OF TREATMENT RESPONSE TO 131I THERAPY FOR PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA IN THE PAST THREE YEARS (Single Institutional Experience)

Egyptian Journal Nuclear Medicine
Volume 25, Issue 2, December 2022, Page 45-62  XML PDF (429.09 K)
Document Type: Original Paper, Therapy
DOI: 10.21608/egyjnm.2022.168501.1068
View on SCiNiTO View on SCiNiTO
Authors
Ahmed Mohamed Badawy email 1; Ahmed Tawakol2; Asmaa Magdy Abdelmoteleb3; Yasser Mohamed Ahmad4; Ahmed Kandil3
1clinical oncology and nuclear medicine- faculty of medicine- Cairo university
2Oncology and Nuclear Medicine Department, Kasr Al-Aini Hospital, Cairo University, Egypt.
3clinical oncology and nuclear medicine department, faculty of medicine, Cairo university
4Department of Nuclear Medicine, Faculty of Medicine , Cairo University
Abstract
ABSTRACT;
Background; The most frequent endocrine cancer is thyroid cancer. Differentiated thyroid carcinoma (DTC) is becoming more common lately. Aim of the work; The objective of this study is to assess the response to radioactive iodine 131 (RAI131) treatment outcome in the institution over the last three years. Methods; Retrospective analysis of data of 223 patients with differentiated thyroid carcinoma between years of 2017 and 2019 at the Nuclear Medicine Unit, Cairo University Hospitals (NEMROCK). Data collection included operative extent, pathology, 131I dose, diagnostic and post-therapeutic radioactive iodine scan and neck ultrasound. Results; Among the 223 patients, 61.9% were ≤45 years, most of them were females (male: female ratio of 1: 2.23). Papillary thyroid carcinoma was the most frequent pathology with incidence 66.8%. There was statistically insignificant difference between low and high doses of iodine in achieving successful residual ablation in low as well as intermediate risk patients. Multivariant analysis of the different risk factors revealed that proper ablative dose, gender, serial serum thyroglobulin measurement, risk stratification were significant prognostic factors. Conclusion; Our data suggest that proper ablative dose, gender, serial serum thyroglobulin measurement, lack of metastatic lesions and risk stratification were significant prognostic predictors for excellent outcome in DTC patients.
Keywords
DTC; RAI131; treatment; response
Statistics
Article View: 21
PDF Download: 7